BIOMAT Database Logo BIOMAT Database Logo

[Calcium antagonists: pharmacological effects and therapeutic indications]. 1983

J P Clozel, and P Théroux, and G Caillé, and M G Bourassa

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006331 Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities. Cardiac Disorders,Heart Disorders,Cardiac Diseases,Cardiac Disease,Cardiac Disorder,Heart Disease,Heart Disorder
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[Preferential therapeutic indications for calcium antagonists].
December 1985, Cardiologia (Rome, Italy),
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review.
January 1984, The Quarterly journal of medicine,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[Calcium antagonists: pharmacological cardiovascular effects of nifedipine].
January 1984, Medicina,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[Calcium antagonists in cardiology: 10 years later. II. Therapeutic indications].
April 1982, La Nouvelle presse medicale,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[Calcium antagonists. Properties and current indications].
April 1984, Recenti progressi in medicina,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
Clinical pharmacological aspects of calcium antagonists and their therapeutic role in hypertension.
January 1985, Journal of cardiovascular pharmacology,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[The pharmacological basis for the therapeutic utilization of calcium antagonists. II].
January 1980, Coeur et medecine interne,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
Calcium channel antagonists: pharmacological considerations.
January 1985, British journal of clinical pharmacology,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
Pharmacological differences between calcium antagonists.
January 1997, European heart journal,
J P Clozel, and P Théroux, and G Caillé, and M G Bourassa
[Pharmacological aspects and therapeutic uses of verapamil and related calcium antagonists (author's transl)].
October 1980, Revista medica de Chile,
Copied contents to your clipboard!